Compare TransMedics Group Inc (TMDX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.00B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.79. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | XLY | |
|---|---|---|
Market Cap | $3.00B | — |
Sector | Technology | — |
52-Week High | $150.42 | $124.52 |
52-Week Low | $61.99 | $105.64 |
Enterprise Value | $3.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
XLY trades at $113.99, down 0.8% today amid bearish technical signals with 18 sell indicators versus 3 buy signals. The ETF maintains 100% analyst buy consensus despite missing key valuation metrics. Recent news highlights consumer discretionary sector opportunities, with XLY positioned as a potential sleeper ETF for Q3 2026 given resilient consumer spending trends and economic conditions.
The outlook remains cautiously optimistic with strong analyst support, though technical weakness and sector concentration risks warrant monitoring. Upside potential exists from consumer spending resilience and economic broadening, while downside risks include market volatility and inflationary pressures affecting discretionary purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
